血液筛检市场规模、份额、成长分析（按产品、技术、最终用户、地区）- 2025 年至 2032 年产业预测

2023 年血液筛检市场规模价值 25 亿美元，预计将从 2024 年的 27.2 亿美元成长到 2032 年的 53 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.7%。

全球对安全血液的需求和筛检技术的进步正在塑造血液筛检市场的未来。随着全球捐血率的增加，需要进行全面的筛检程序以确保捐血者的安全。这一趋势在政府大力支持捐血倡议的国家尤其明显，这些国家的良好基础设施和公众意识推动着捐血的增加。最近捐血的激增凸显了对先进检测方法来检测感染疾病的需求，从而确保受血者的安全。大众对爱滋病毒、B型肝炎、C肝和兹卡病毒等感染疾病的健康担忧进一步凸显了采用先进筛检技术的重要性。因此，化学冷光免疫检测(CLIA) 和核酸增幅检查(NAT) 等技术正成为世界各地血液筛检实验室的标准。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 专利分析
• 监管分析
• 技术分析
• 案例研究

血液筛检市场规模（按产品和复合年增长率） (2025-2032)

• 市场概览
• 试剂和套件
  • 天然试剂与套件
  • ELISA 试剂和套件
  • 其他试剂和套件
• 装置
  • 租赁购买
  • 完成购买
• 软体和服务

血液筛检市场规模（依技术及复合年增长率） (2025-2032)

• 市场概览
• 核酸检测（NAT）
  • 转录介导扩增（TMA）
  • 即时聚合酵素链锁反应（RT-PCR）
• 血清学/免疫检测
  • 化学冷光免疫检测（CLIA）
  • 萤光免疫分析法（FIA）
  • 比色免疫检测/ELISA（CI/ELISA）
• 快速检测
• 西方墨点法
• 次世代定序（NGS）

血液筛检市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 血库
• 医院

血液筛检市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Abbott Laboratories（USA）
• Becton, Dickinson and Company（USA）
• Bio-Rad Laboratories, Inc.（USA）
• bioMerieux SA（France）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Grifols, SA（Spain）
• Hologic, Inc.（USA）
• Quotient Limited（UK）
• Siemens Healthineers AG（Germany）
• Sysmex Corporation（Japan）
• Thermo Fisher Scientific Inc.（USA）
• Danaher Corporation（USA）
• Grifols Diagnostic Solutions Inc.（USA）
• Haemonetics Corporation（USA）
• Natera, Inc.（USA）
• Novartis International AG（Switzerland）
• Promega Corporation（USA）

结论和建议

Blood Screening Market size was valued at USD 2.5 billion in 2023 and is poised to grow from USD 2.72 billion in 2024 to USD 5.3 billion by 2032, growing at a CAGR of 8.7% during the forecast period (2025-2032).

The global demand for safe blood, coupled with advancements in screening technologies, is shaping the future of the blood screening market. As blood donation rates rise worldwide, the need for comprehensive screening procedures becomes essential to ensure donor safety. This trend is particularly prevalent in countries with robust government support for blood collection initiatives, where superior infrastructure and public awareness drive increased contributions. Recent surges in blood donations highlight the necessity for advanced testing methods to detect infections, thereby safeguarding recipients. Public health concerns over infectious diseases like HIV, hepatitis B and C, and Zika virus further emphasize the importance of adopting refined screening techniques. Consequently, technologies such as chemiluminescence immunoassays (CLIA) and nucleic acid amplification tests (NAT) are becoming standard in blood screening facilities globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Blood Screening market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Blood Screening Market Segments Analysis

Global Blood Screening Market is segmented by Product, Technology, End User and region. Based on Product, the market is segmented into Reagents & Kits, Instruments and Software & Services. Based on Technology, the market is segmented into Nucleic Acid Tests (NAT), Serology/Immunoassays, Rapid Tests, Western Blot Assays and Next-Generation Sequencing (NGS). Based on End User, the market is segmented into Blood Banks and Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Blood Screening Market

The blood screening market is primarily driven by advancements in the understanding and response to infectious diseases, particularly the surge in bacterial and viral infections. There is a marked increase in the utilization of blood tests among healthcare professionals, fueled by evolving public health priorities aimed at monitoring disease outbreaks and guaranteeing the safety of blood transfusions. This trend reflects a heightened awareness of blood-borne infections and the critical need for early detection, prompting hospitals and clinics to invest in cutting-edge blood screening technologies. As a result, the market is poised for continued growth in the coming years, spurred by an emphasis on safety and preventive healthcare measures.

Restraints in the Blood Screening Market

A significant barrier to the blood screening market is the high cost associated with advanced screening tools and technologies. Many healthcare facilities, particularly in developing regions, find it challenging to afford the expensive blood screening equipment necessary for thorough testing. This financial constraint restricts their ability to implement comprehensive testing protocols, ultimately hindering market growth. The high costs not only limit the initial acquisition of the technology but also pose ongoing maintenance and operational expenses, further complicating the situation for healthcare providers and preventing them from keeping pace with advancements in blood screening practices.

Market Trends of the Blood Screening Market

The blood screening market is experiencing a significant shift towards point-of-care (POC) testing, driven by the need for rapid and decentralized diagnostics in healthcare settings. This trend enhances the delivery of near-instant results for essential laboratory tests, eliminating the delays associated with traditional sample processing at centralized labs. POC testing is increasingly being integrated into emergency rooms, outpatient clinics, and other medical facilities, facilitating quicker clinical decisions and improving patient experiences. As technological advancements continue to diversify POC blood screening options, the market is poised for robust growth, reflecting an increasing emphasis on efficiency and quality care in healthcare delivery.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Patent Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies

Global Blood Screening Market Size by Product & Service & CAGR (2025-2032)

• Market Overview
• Reagents & Kits
  • Nat Reagents & Kits
  • Elisa Reagents & Kits
  • Other Reagents & Kits
• Instruments
  • Rental Purchase
  • Outright Purchase
• Software & Services

Global Blood Screening Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Nucleic Acid Tests (NAT)
  • Transcription-Mediated Amplification (TMA)
  • Real-Time Polymerase Chain Reaction (RT-PCR)
• Serology/Immunoassays
  • Chemiluminescent Immunoassays (CLIA)
  • Fluorescent Immunoassays (FIA)
  • Colorimetric Immunoassays/ELISA (CI/ELISA)
• Rapid Tests
• Western Blot Assays
• Next-Generation Sequencing (NGS)

Global Blood Screening Market Size by End User & CAGR (2025-2032)

• Market Overview
• Blood Banks
• Hospitals

Global Blood Screening Market Size & CAGR (2025-2032)

• North America (Product & Service, Technology, End User)
  • US
  • Canada
• Europe (Product & Service, Technology, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product & Service, Technology, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product & Service, Technology, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product & Service, Technology, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quotient Limited (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols Diagnostic Solutions Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haemonetics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations